Upping the ante on antibodies

Article Abstract:

Researches eventually figured out ways to reduce the problem of immunogenicity by replacing mouse sequences (monoclonal antibodies) in part or completely with human ones and antibodies exploded onto the market. The success of antibodies have, thus, infused biotech companies with cash and made pharmaceutical companies eager to invest again.

Market share, Monoclonal antibodies, Company market share

---

Industry concerns mount over CIRM grants

Article Abstract:

The biotechnology industry is concerned about the grants provided by the California Institute of Regenerative Medicine (CIRM). The CIRM's plans for offering grants and the revenue-sharing schemes for CIRM-funded technologies and projects are discussed.

Financial management, California, Evaluation, Finance, Research grants, Research funding, Company financing

---

New-wave diagnostics

Article Abstract:

A new class of high-cost diagnostic companies is emerging into the commercial and regulatory environment that isn't designed for them. The future of such companies is discussed in the context of challenges faced by them to survive in their new roles.

Forecasts, trends, outlooks, Sales & consumption, United States, Growth, Company growth, Industry sales and revenue, Industry forecasts

Similar abstracts:

• Abstracts: Emily the Strange Sinimints Cinnamon Flavored Candies. Hello Kitty Sours Sour Candies
• Abstracts: Auspicious antigens. Immunotherapy dispenses with tumor antigens. Immunosuppressive networks in the tumor environment and their therapeutic relevance
• Abstracts: Empowering the inventor: The case of monoclonal antibodies. Flexibility: The guiding principle for antibody manufacturing
• Abstracts: Empowering the inventor: The case of monoclonal antibodies. The patentability of antibodies in the United States
• Abstracts: A new role for scientists in the biological weapons convention. Overhauling oversight: European drug legislation

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.